On Tuesday, MAIA Biotechnology Inc. announced a treatment update on its Phase 2 THIO-101 trial, which combines THIO with Regeneron Pharmaceuticals’ REGN cemiplimab (Libtayo) in patients with advanced non-small cell lung cancer who have failed two or more standard treatment regimens.
The treatment plan for the clinical trial is cycled every 3 weeks, with 180 mg of THIO administered in 60 mg increments on days 1, 2, and 3, immune activation (no administration) on day 4, and cemiplimab 350 mg on day 5.
As of the latest clinical cutoff date of June 12, 2024:
Six patients remain on treatment after at least 12 months of treatment. THIO followed by cemiplimab was well tolerated throughout the study with much less toxicity than standard of care. Continuation of treatment beyond 12 months demonstrated the safety, efficacy and continued benefit of MAIA’s novel telomere-targeted NSCLC treatment.
“The longest-treated patient to date has completed 21 cycles of THIO sequencing with CPI, and six patients beyond the 12-month survival follow-up remain on treatment,” said Vlado Vitoc, Chairman and CEO of MAIA.
In June, MAIA Biotechnology announced new efficacy data from its Phase 2 THIO-101 trial.
Latest results show that THIO + CPI in third-line treatment had a favorable overall response rate (ORR) of 38% and disease control rate (DCR) of 85%.
The disease control rate (DCR) for THIO was 85% compared to 25-35% for standard of care chemotherapy. 65% of patients exceeded an overall survival (OS) threshold of 5.8 months. 85% of patients exceeded a progression-free survival (PFS) threshold of 2.5 months. Median survival follow-up is currently 9.1 months (n=20).
Price Action: MAIA shares were down 14.25% to $3.31 as of last check on Tuesday.
Read next:
Image created using artificial intelligence via Midjourney.
Market news and data provided by Benzinga API
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
